PETCT and lung cancer: Selecting those likely to benefit and sparing those with little to gain
Lung cancer is the third commonest cancer in the UK and 75% of patients present with advanced disease (stage III or IV); 10-year survival is only 5%. PETCT is best considered as a tool that aids the selection of those most likely to benefit from potentially curative treatment, either surgical resection or radical radiotherapy, while […]
Dr Peter J G Garmany
Queen Elizabeth University Hospital and West of Scotland Cancer Centre